TY - JOUR
T1 - Pachyonychia congenita type 2, N92S mutation of keratin 17 gene
T2 - clinical features, mutation analysis and pathological view
AU - Cogulu, Ozgur
AU - Onay, Huseyin
AU - Aykut, Ayca
AU - Wilson, Neil J.
AU - Smith, Frances J. D.
AU - Dereli, Tugrul
AU - Ozkinay, Ferda
PY - 2009/10
Y1 - 2009/10
N2 - Pachyonychia congenita (PC) type 2 is a rare inherited genetic disease characterized by hypertrophic nail dystrophy, palmoplantar hyperkeratosis and multiple pilosebaceous cysts. In some cases, natal teeth and hair abnormalities may be present. It is caused by mutations in keratin 17 or its expression partner keratin 6b. Here, an N92S (p.Asn92Ser) germline keratin 17 gene mutation in a pachyonychia congenita type 2 female patient is presented. The pedigree includes the 15 members of a family who showed a severe expression of the phenotype for six generations with a similar clinical picture consisting of sebaceous cysts, nail dystrophy, hyperkeratosis, hair abnormalities, natal teeth, hoarseness and hyperhydrosis. In conclusion, we emphasize the importance of diagnosing and managing pachyonychia congenita in childhood for the assistance of affected children and for the development of potential therapies.
AB - Pachyonychia congenita (PC) type 2 is a rare inherited genetic disease characterized by hypertrophic nail dystrophy, palmoplantar hyperkeratosis and multiple pilosebaceous cysts. In some cases, natal teeth and hair abnormalities may be present. It is caused by mutations in keratin 17 or its expression partner keratin 6b. Here, an N92S (p.Asn92Ser) germline keratin 17 gene mutation in a pachyonychia congenita type 2 female patient is presented. The pedigree includes the 15 members of a family who showed a severe expression of the phenotype for six generations with a similar clinical picture consisting of sebaceous cysts, nail dystrophy, hyperkeratosis, hair abnormalities, natal teeth, hoarseness and hyperhydrosis. In conclusion, we emphasize the importance of diagnosing and managing pachyonychia congenita in childhood for the assistance of affected children and for the development of potential therapies.
U2 - 10.1007/s00431-008-0908-6
DO - 10.1007/s00431-008-0908-6
M3 - Article
C2 - 19107515
SN - 0340-6199
VL - 168
SP - 1269
EP - 1272
JO - European Journal of Pediatrics
JF - European Journal of Pediatrics
IS - 10
ER -